New Search

If you are not happy with the results below please do another search

1271 search results for:

101

EUROIMMUN unveils UNIQO 160 automated indirect immunofluorescence test system

Revvity’s EUROIMMUN business has launched the UNIQO 160, an automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics. Now available in countries accepting the CE mark, this all-in-one solution increases the efficiency of the entire IIFT process, encompassing sample preparation, incubation, washing and mounting of slides as well as image acquisition and analysis.

102

Oncodesign Services opens access to ImaginAb’s CD8 ImmunoPET technology

Oncodesign Services, a leading Contract Research Organization specialized in drug discovery and preclinical services in oncology and immuno-inflammation, has executed a Preclinical License and Supply Agreement with ImaginAb for the use of their investigational CD8 ImmunoPET (89Zr crefmirlimab berdoxam) technology. ImaginAb, a biotechnology company, developed CD8 ImmunoPET, a 89Zr PET imaging agent to enable the […]

103

Indica Labs offers HALO software as fully managed AWS cloud service

Indica Labs is now offering its HALO digital pathology software portfolio as a fully managed cloudhosted environment powered by Amazon Web Services (AWS). The service enables organizations to benefit from Indica Labs’ software development and cloud deployment expertise while maintaining full ownership and control over their AWS account.

108

Indica Labs offers HALO software as fully managed AWS cloud service

Indica Labs is now offering its HALO digital pathology software portfolio as a fully managed cloud-hosted environment powered by Amazon Web Services (AWS). The service enables organizations to benefit from Indica Labs’ software development and cloud deployment expertise while maintaining full ownership and control over their AWS account. 

109

New analgesic shows positive results in pre-clinical trial

Danish biotech Tetra Pharm Technologies announced promising results from a pre-clinical in vitro trial of its pain-relieving drug – TPT0301 – using a novel drug delivery technology. It was compared against more commonly used formulations for drug delivery in the oral cavity.